Targeting Phosphoinositide 3-Kinase γ in Airway Smooth Muscle Cells to Suppress Interleukin-13-Induced Mouse Airway Hyperresponsiveness

Haihong Jiang, Yan Xie, Peter W. Abel, Myron L. Toews, Robert G. Townley, Thomas B. Casale, and Yaping Tu

Departments of Pharmacology (H.J., Y.X., P.W.A., Y.T.) and Internal Medicine (R.G.T., T.B.C.), Creighton University School of Medicine, Omaha, Nebraska; and Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska (M.L.T.)

Received November 4, 2011; accepted April 26, 2012

ABSTRACT

We recently reported that phosphoinositide 3-kinase γ (PI3Kγ) directly regulates airway smooth muscle (ASM) contraction by modulating Ca2+ oscillations. Because ASM contraction plays a critical role in airway hyperresponsiveness (AHR) of asthma, the aim of the present study was to determine whether targeting PI3Kγ in ASM cells could suppress AHR in vitro and in vivo. Intranasal administration into mice of interleukin-13 (IL-13; 10 μg per mouse), a key pathophysiologic cytokine in asthma, induced AHR after 48 h, as assessed by invasive tracheostomy. Intranasal administration of a broad-spectrum PI3K inhibitor or a PI3Kγ-specific inhibitor 1 h before AHR assessment attenuated IL-13 effects. Airway responsiveness to bronchoconstrictor agonists was also examined in precision-cut mouse lung slices pretreated without or with IL-13 for 24 h. Acetylcholine and serotonin dose-response curves indicated that IL-13-treated lung slices had a 40 to 50% larger maximal airway constriction compared with controls. Furthermore, acetylcholine induced a larger initial Ca2+ transient and increased Ca2+ oscillations in IL-13-treated primary mouse ASM cells compared with control cells, correlating with increased cell contractility. As expected, PI3Kγ inhibitor treatment attenuated IL-13-augmented airway contractility of lung slices and ASM cell contraction. In both control and IL-13-treated ASM cells, small interfering RNA-mediated knockdown of PI3Kγ by 70% only reduced the initial Ca2+ transient by 20 to 30% but markedly attenuated Ca2+ oscillations and contractility of ASM cells by 50 to 60%. This report is the first to demonstrate that PI3Kγ in ASM cells is important for IL-13-induced AHR and that acute treatment with a PI3Kγ inhibitor can ameliorate AHR in a murine model of asthma.

Introduction

Airway hyperresponsiveness (AHR) is exaggerated constriction of the airways in response to bronchoconstrictor stimuli (Hargreave et al., 1985). It is a key diagnostic criterion of asthma, and improvement in AHR is associated with better control of asthma (Busse, 2010). Many factors, including airway inflammation and remodeling, contribute to AHR (Fahy et al., 2000; Berend et al., 2008; Casale and Stokes, 2008), but it is increased ASM contractility that is directly responsible for AHR (Shore, 2004; An et al., 2007). G protein-coupled receptors (GPCRs) are important regulators of multiple cell types involved in asthma. Excessive activation of different bronchoconstrictor GPCRs, such as muscarinic, serotonin, endothelin B, leukotriene, and proton-sensing OGR1 receptors in ASM, contributes to AHR of asthma (Deshpande and Penn, 2006; Saxena et al., 2011). Drugs targeting specific GPCRs are used as therapies for AHR in asthma (Shore and Moore, 2003; Currie and McLaughlin, 2006; Hanania et al., 2010; Moulton and Fryer, 2011), yet asthma still affects 23 million Americans, causing significant morbidity. The strategy of inhibiting a single GPCR is limited because airway constriction can be induced by different GPCRs simultaneously, thereby having bronchoconstrictor signal redundancy. Targeting downstream molecules that mediate integrated signals from multiple GPCRs in ASM cells could provide an...
effective alternate strategy to attenuate excessive airway constriction in asthma.

The type I phosphoinositide 3-kinase (PI3K) family includes α, β, γ, and δ isomers. PI3Kγ is only activated by GPCRs, whereas PI3Kα, β, and δ are typically stimulated by receptor tyrosine kinases (Leopoldt et al., 1998; Vanhaesebroeck and Waterfield, 1999). PI3Kγ has been implicated in the pathogenesis of asthma. For example, knockout of PI3Kγ or treatment with aerosolized TG100-115, an inhibitor of PI3Kγ, markedly reduced allergen-induced asthma in experimental animals, including eosinophilic airway inflammation and AHR (Doukas et al., 2009; Lim et al., 2009; Takeda et al., 2009). Thus, PI3Kγ may be a novel therapeutic target in asthma and other respiratory diseases (Marwick et al., 2010). The mechanism underlying the pathological importance of PI3Kγ in asthma has been considered indirect, through release of inflammatory cell mediators. However, our recent study showed that PI3Kγ is expressed in ASM cells and controls contractility of airways through regulation of Ca2+ oscillations in ASM cells (Jiang et al., 2010). Thus, PI3Kγ in ASM cells may also exert direct effects on the airway constriction that contributes to pathologic AHR.

The T-helper type 2 cytokine interleukin-13 (IL-13) is thought to play a central role in the development of airway inflammation and AHR in asthma. IL-13 is increased in airways of asthmatics and correlates with AHR (Saha et al., 2008). IL-13-deficient mice are protected from development of allergen-induced AHR (Walter et al., 2001), whereas administration of IL-13 is sufficient to induce AHR in mice (Wills-Karp et al., 1998). In humans, anti-IL-13 monoclonal antibody has recently been shown to have positive therapeutic effects in asthma (Corren et al., 2011; Gauvreau et al., 2011).

There is compelling evidence that IL-13 may cause AHR via a direct effect on ASM. ASM cells express IL-13 receptors and respond to IL-13, resulting in augmented Ca2+ mobilization and contractility of ASM cells (Eum et al., 2005; Sathish et al., 2009). We recently reported that a PI3Kγ-specific inhibitor, but not inhibitors of other PI3K isofoms, can attenuate contracture of ASM cells via modulating Ca2+ oscillations (Jiang et al., 2010). The purpose of the present study was to determine whether pharmacologic blockade or small interfering RNA (siRNA)-mediated knockdown of PI3Kγ can also suppress IL-13-induced ASM hypercontractility in vitro and AHR in vivo. Using animal, tissue, and cellular models, we demonstrated that PI3Kγ activation is important in development of AHR and that directly targeting PI3Kγ expression or activity in ASM cells can suppress the AHR associated with asthma.

Materials and Methods

Animals. The original breeding pairs of C57BL/6J mice used in our study were a gift from Dr. Stephen J. Gold (University of Texas Southwestern Medical Center, Dallas, TX). The mice were obtained by in-house breeding. All experiments were approved by the Creighton University Institutional Animal Care and Use Committee.

Reagents. Murine recombinant IL-13 was purchased from PeproTech (Rocky Hill, NJ). Hanks’ balanced salt solution supplemented with 10 mM HEPES buffer, penicillin, streptomycin, amphotericin B, fura-2/acetoxymethyl ester, and Pluronic F-127 were all purchased from Invitrogen (Carlsbad, CA). PI3Kγ inhibitor II [5-(2,2-difluoro-benzo-[1,3]dioxol-5-ylmethylene)-thiazolidine-2,4-dione]; a broad-spectrum PI3K inhibitor, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002); and its inactive analog 2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one (LY303511) were obtained from EMD Biosciences (San Diego, CA). Rabbit PI3Kγ and PI3Kα antibodies and IRDye800-labeled anti-rabbit IgG were purchased from Cell Signaling Technology Inc. (Danvers, MA) and LI-COR Bioscience (Lincoln, NE), respectively. Acetyltetrahexanol (ACh) and serotonin were purchased from Sigma-Aldrich (St. Louis, MO), and ON-TARGETplus SMARTpool siRNA targeting mouse PI3Kγ was purchased from Thermo Scientific (Lafayette, CO). Unless indicated otherwise, other reagents were purchased from either Sigma-Aldrich or Fisher Scientific (Waltham, MA).

Intranasal Challenge with Murine Recombinant IL-13 and Measurement of Airway Resistance of Mice. A murine model of AHR was established as described previously (Yang et al., 2001; Townley et al., 2009). In brief, 8- to 10-week-old male mice (body weight, 20 g) were anesthetized and intranasally administered 10 μg of IL-13 dissolved in 50 μl of phosphate-buffered saline (PBS) containing 0.1% BSA or BSA in PBS solution alone (control). Methacholine-induced airway resistance (R_l) was measured 48 h later. To assess the effect of PI3Kγ blockade on IL-13-induced AHR, mice were administered PI3Kγ inhibitor II, LY294002, LY303511, or 20 μl of DMSO vehicle intranasally 1 h before airway resistance measurements. Several doses of inhibitors were tested in preliminary studies, and a dose of 20 mg/kg was used in the final experiments.

Airway resistance of anesthetized mice, defined as the pressure driving respiration divided by flow, was assessed by invasive tracheotomy as described previously (Guedes et al., 2006). In brief, anesthetized mice were placed into a plethysmograph chamber (Buxco, Wilmington, NC) and ventilated mechanically at a rate of 140 breaths per minute and a tidal volume of 200 μl. Mice were challenged with 2 μl of saline (baseline) followed by cumulative doses of methacholine (6.25–100 mg/ml) without or with 10 μg of inhibitors or inactive LY303511 using an ultrasonic nebulizer. The data were collected by the FinePointe RC System (Buxco) for 3 min. The response to each methacholine dose was expressed as relative R_l (cm H2O/ml/s).

Preparation of Lung Slices and Treatment with IL-13. Lung slices were prepared as described previously (Bergner and Sanderson, 2002; Jiang et al., 2010). Lung slices of 150-μm thickness cultured in serum-free Dulbecco’s modified Eagle’s medium were treated without or with IL-13 (100 ng/ml) for 24 h and subjected to airway constriction measurements.

Measurement of Airway Constriction. Lung slices with airways that were completely lined by epithelial cells with beating cilia were selected (Jiang et al., 2010). Airways with similar cross-sectional areas, which averaged 61,837 ± 1436 μm2, were used for all studies. The slices were placed on glass coverslips in a self-constructed chamber, and phase-contrast images were recorded with a digital CoolSNAP HQ2 camera (Photometrics, Tucson, AZ) using Image-Pro Plus software (Media Cybernetics, Bethesda, MD). Frames were captured in time-lapse mode (one frame per 3 s) and time-dependent changes in the cross-sectional areas of the airway lumen were measured by pixel summing using Image-Pro Plus. A decrease in the cross-sectional area was considered to be airway constriction.

RNA Interference by Dual Transfection. Mouse tracheal ASM cell isolation and culture were described previously (Jiang et al., 2010). Only α-smooth muscle actin staining positive cells with the classic “hill and valley” morphology, passages 3 to 6, were used. ASM cells (8 × 105 in 100 μl) were electroporated with 300 nM control siRNA (negative control no. 1 siRNA; Ambion, Austin, TX) or ON-TARGETplus SMARTpool siRNA for PI3Kγ using Nucleofector kits for smooth muscle and the Amazax Nucleofector System (Lonza Walkersville Inc., Walkersville, MD). Cells were seeded on six-well plates.
The following day, adherent ASM cells were retransfected with the same siRNA using Lipofectamine 2000 as described previously (Wong et al., 2011). Two days later, cells were harvested for Western blot analysis of PI3Kα and PI3Kγ, Ca²⁺ signaling, and cell contraction assays.

**Western Blot Analysis.** Protein was extracted from ASM cells using 1× radioimmunoprecipitation assay complete lysis buffer (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Protein concentrations were determined using the Bradford assay (Bio-Rad Laboratories, Hercules, CA). Protein samples (60 µg) were loaded on 8% SDS polyacrylamide gels, electrophoresed, and transferred onto a polyvinylidene difluoride membrane. Membranes were probed with a PI3Kα- or PI3Kγ-specific antibody followed by IRDye800-labeled anti-rabbit IgG. β-Actin was used as a loading control. The signal was visualized using an Odyssey IR imaging system (LI-COR Bioscience).

**Measurement of Contraction of Mouse Tracheal ASM Cells.** Primary ASM cells were sparsely plated onto glass coverslips and cultured overnight. The coverslips were mounted in a custom-made Plexiglas chamber, and images were taken using an inverted Nikon TE2000 microscope equipped with a CoolSNAP HQ2 digital camera (Photometrics). An initial recording (time, 0 min) was made to obtain the size of quiescent cells. Various concentrations of ACh or serotonin were added to the chamber at 30 s, and images were recorded at 10-s intervals for 5 min. Contractility was assayed using Image-Pro Plus as described previously (Govindaraju et al., 2006; Jiang et al., 2010). Only those cells with a distinct longitudinal axis and clearly visible cell substrate boundaries were selected for analysis. Surface area was obtained by tracing the outer boundary of the cell. Three experiments were performed on multiple days with 50 cells recorded. The extent of contraction was calculated as the ratio of the change in surface area to the initial value.

**Measurement of Intracellular-Free Ca²⁺ and Ca²⁺ Oscillation Frequency of Mouse Tracheal ASM Cells.** Fura-2-loaded cells were excited at 340 and 380 nm using a DeltaRAM X monochromator (Photon Technology International, Lawrenceville, NJ). Fluorescent images of individual cells were acquired at one frame per second for at least 300 s to characterize Ca²⁺ transients and Ca²⁺ oscillations after ACh stimulation. The intracellular-free calcium concentration in selected regions of interest (3 × 3 pixels) of individual cells is presented as the ratio of the fluorescence intensities (500-nm emission) at excitation of 340 nm compared with 380 nm. A fluorescence signal was defined as a Ca²⁺ oscillation only if the peak amplitude was greater than twice the background noise. Ca²⁺ oscillation frequency was measured as the inverse of the average time between two oscillations. Data are averages from at least 30 cells.

**Data Analysis.** Data are expressed as means ± S.E. Groups were compared using a Student’s t test for unpaired observations or a two-way analysis of variance (ANOVA) with the Bonferroni correction where there were multiple comparisons. A probability level (p) of 0.05 was used to determine statistical significance.

**Results**

**The Effect of PI3Kγ Blockade on IL-13-Induced Mouse AHR In Vivo.** The airway resistance (Rₐ) in response to increasing doses of methacholine challenge was assessed in anesthetized mice (Fig. 1A). In response to inhaled methacholine, mice challenged with intranasal administration of IL-13 (10 µg per mouse) showed a significantly increased Rₐ compared with control mice (Fig. 1B). The methacholine concentration required to double the basal airway resistance was decreased from 60 mg/ml in control mice to 30 mg/ml in IL-13-challenged mice, suggesting that intranasal administration of IL-13 caused AHR. Preadministration of PI3Kγ-specific inhibitor II significantly attenuated IL-13-augmented Rₐ in response to methacholine (Fig. 1B). Because our previous studies showed that a broad-spectrum PI3K inhibitor, LY294002, also attenuated PI3Kγ-dependent mouse airway constriction (Jiang et al., 2010), we also examined the effects of LY294002 on IL-13-augmented mouse Rₐ in vivo. As shown in Fig. 1C, preadministration of LY294002, but not its inactive analog LY303511, attenuated IL-13-augmented Rₐ in response to methacholine. Thus, PI3Kγ activation seems to be critical for IL-13-induced AHR in mice in vivo.

**IL-13 Augments Airway Contractility of Mouse Lung Slices In Vitro.** To determine whether IL-13-induced AHR is due to changes of airway contractility, precision-cut mouse lung slices were incubated without or with IL-13 (100 ng/ml) for 24 h, and airway constriction induced by ACh or serotonin...
was examined. As shown in Fig. 2A, IL-13 treatment increased airway constriction induced by 1 μM ACh or serotonin. The dose-response curves shown in Fig. 2, B and C, indicate that IL-13 treatment increased ACh- or serotonin-induced maximal airway constriction by 40 to 50%. However, IL-13 treatment had no effects on the median effective concentrations (EC50) for ACh (control, 74 ± 8 nM; IL-13, 83 ± 17 nM) or serotonin (control, 43 ± 4 nM; IL-13, 45 ± 6 nM). Thus, IL-13 treatment did not affect the potency of these bronchoconstrictors.

Effects of PI3K Blockade on IL-13-Augmented Airway Contractility of Lung Slices. Our previous study showed that PI3K directly controls contractility of airways in response to ACh in cultured lung slices (Jiang et al., 2010). To determine whether PI3K is also involved in IL-13-augmented airway contractility, lung slices were treated without or with IL-13 for 24 h, and contraction of airways was then measured in the absence or presence of 10 μM PI3K inhibitor II. As shown in Fig. 3, PI3K inhibitor II reduced ACh- and serotonin-induced airway constriction of control lung slices by 40 and 70%, respectively, whereas airway constriction of IL-13-treated lung slices was decreased by 60 and 80%, respectively. It is interesting to note that, in the presence of PI3K inhibitor II, there was no significant difference in ACh- or serotonin-induced airway constriction between control and IL-13-treated lung slices (Fig. 3), suggesting that PI3K blockade abolished IL-13-augmented airway constriction. Thus, PI3K pathways are involved in both normal airway constriction and in IL-13-induced airway hypercontractility.

Blockade or siRNA-Mediated Knockdown of PI3Kα Attenuates IL-13-Augmented Contraction of Isolated Mouse ASM Cells. There is compelling evidence that IL-13 may cause AHR via a direct effect on ASM. Indeed, IL-13 treatment increased 10 μM ACh-induced ASM cell contractions by approximately 60% (Fig. 4A). Treatment of ASM cells with PI3K inhibitor II (10 μM) for 10 min, and ACh- or serotonin-induced airway constriction was measured as described under Materials and Methods. Bronchoconstrictor ligands were then washed out, lung slices were treated with PI3K inhibitor II (10 μM) for 10 min, and ACh- or serotonin-induced airway constriction was remeasured. Data are means ± S.E., using six lung slices from four (A) or five (B) mice. Statistical analysis using ANOVA with the Bonferroni correction was performed on the mean data from each mouse.
approximately 70% but not PI3Kα protein expression compared with a negative control siRNA. ACh-induced ASM cell contraction was decreased by 40 to 50% (Fig. 4C), which is consistent with our results using PI3K inhibitor II (Fig. 4A) (Jiang et al., 2010). More importantly, siRNA-mediated knockdown of endogenous PI3Kγ largely blocked IL-13-augmented ASM cell contractility (Fig. 4C).

**siRNA-Mediated Knockdown of PI3Kγ Inhibits IL-13-Augmented Intracellular Ca^2+ Signaling in Isolated Mouse ASM Cells.** Intracellular Ca^2+ is the key signaling molecule for ASM contraction. Consistent with previous reports (Roux et al., 1997; Jiang et al., 2010), ACh-induced increase in intracellular Ca^2+ consisted of an initial Ca^2+ transient that is responsible for initial contraction, followed by Ca^2+ oscillations that are critical for maintenance of sustained airway constriction (Fig. 5A). Compared with control ASM cells, IL-13-treated ASM cells showed a larger initial Ca^2+ transient, followed by increased Ca^2+ oscillations (Fig. 5A), correlating with increased cell contraction (Fig. 4, A and C). On average, IL-13 treatment increased the Ca^2+ transient and Ca^2+ oscillation frequency of mouse ASM cells by approximately 40% (Fig. 5, B and C). It is interesting to note that, in both control and IL-13-treated ASM cells, siRNA-mediated knockdown of PI3Kγ only reduced the initial Ca^2+ transient by 20 to 30% (Fig. 5B) but more markedly attenuated Ca^2+ oscillations by 50 to 60% (Fig. 5C), correlating with decreased cell contraction (Fig. 4C).

**Discussion**

In the present study, we report for the first time that intranasal administration of a PI3Kγ inhibitor can attenuate IL-13-induced AHR in mice. Furthermore, our studies show that targeting PI3Kγ, using a pharmacologic inhibitor or RNA interference, suppresses IL-13-augmented Ca^2+ oscillations and contractility of ASM cells.

IL-13 is thought to play a central role in the development of airway inflammation and AHR in asthma. Previous studies (Wills-Karp et al., 1998; Yang et al., 2001) have shown that intranasal administration of IL-13 induced AHR as early as 6 h after administration, long before significant inflammation has occurred, followed by an amplified and sustained AHR that peaked at 48 h. Using this IL-13-challenged murine model of AHR, we demonstrate that intranasal administration of one dose of IL-13 into naive mice for 48 h produced greater airway resistance to inhaled methacholine compared with control mice, an indication of robust AHR in mice. Consistent with our previous findings in vitro,

**Fig. 5.** siRNA-mediated knockdown of PI3Kγ attenuated IL-13-augmented Ca^2+ oscillations in primary mouse ASM cells. A, a concentration of 1 μM ACh induced Ca^2+ mobilization (Fura-2 as a probe) of mouse ASM cells. The intracellular Ca^2+ concentration is presented as the ratio of the fluorescence intensities at an excitation of 340 nm compared with 380 nm (F340/F380). These data were quantified and are shown in B and C. B and C, in control and IL-13-treated ASM cells, siRNA-mediated knockdown of PI3Kγ only partially reduced the initial Ca^2+ transient (B) but more markedly attenuated Ca^2+ oscillations (C) of ASM cells in response to ACh. Data are means ± S.E. and represent at least 30 cells from three separate experiments performed on multiple days. Statistical comparisons used ANOVA with the Bonferroni correction.

**Fig. 4.** Targeting PI3Kγ to attenuate IL-13-augmented contraction of primary mouse ASM cells. A, blockade of PI3Kγ attenuated IL-13-augmented contraction of mouse ASM cells. ASM cells were treated without (control) or with IL-13 (100 ng/ml) for 24 h. Cells were then exposed to 10 μM ACh in the presence of PI3Kγ inhibitor II (10 μM) or vehicle (0.1% DMSO). Representative images of an initial recording (None, 0 min) and after 5-min exposure to 10 μM ACh are shown on the left. The extent of contraction, calculated as the percentage change in cell-surface area, is shown on the right. Mouse ASM cells were also dual transfected with PI3Kγ siRNA or negative (Neg) siRNA for 48 h and treated without (control) or with IL-13 (100 ng/ml) for 24 h. B, Western blot analysis of PI3Kγ, PI3Kα, and β-actin expression levels in IL-13-treated mouse ASM cells (left), analyzed by measuring band density with β-actin as the normalizing control (right). Data represent means ± S.E. of three independent experiments performed in duplicate. C, siRNA-mediated knockdown of PI3Kγ inhibited IL-13-augmented ASM cell contraction in response to 10 μM ACh. Data in A and C are means ± S.E. and represent 50 cells from three separate experiments performed on multiple days. Statistical comparisons used ANOVA with the Bonferroni correction.
PI3K inhibitor II attenuated airway constriction to the contractile agonist methacholine in naive mice. More importantly, intranasal administration of PI3K inhibitor II blocked IL-13-induced AHR in mice.

PI3K inhibitor II exhibits great selectivity for PI3K over other PI3K isoforms (20–100-fold) and shows little effect on a large panel of receptors, unrelated enzymes, ion channels, and commonly studied kinases. In our preliminary studies, we tested several doses of PI3K inhibitor II in IL-13-challenged mice at different times before methacholine challenge and found that intranasal administration of PI3K inhibitor II at a dose of 20 mg/kg, 60 min before airway resistance measurements, is sufficient to attenuate IL-13-induced AHR. Because the local concentration of this inhibitor in mouse airways in vivo is unknown, whether it is still selective in vivo at the dose used remains to be determined. However, we found that preadministration of LY294002, a broad-spectrum PI3K inhibitor, but not its inactive analog LY303511, attenuated IL-13-induced AHR in mice. This is consistent with our previous results showing that LY294002 also attenuated PI3K-dependent mouse airway constriction (Jiang et al., 2010). Thus, PI3K inhibition seems to be critical for IL-13-induced AHR in mice.

The role of PI3Ks in asthma has been studied previously. These studies, using two broad-spectrum inhibitors of PI3K, wortmannin and LY294002, suggested that PI3K contributes to the pathogenesis of asthma by affecting the recruitment, activation, and apoptosis of inflammatory cells (Ezeamuzie et al., 2001; Kwak et al., 2003). More recent studies have been focused on the involvement of PI3K isoforms in asthma. Lee et al. (2006) found that inhibition of PI3K regulated allergic airway inflammation and AHR in an ovalbumin-challenged murine model of asthma. PI3K has been implicated in the pathogenesis of asthma, but its mechanism has been considered indirect, through release of inflammatory cell mediators (Lim et al., 2009; Takeda et al., 2009). We recently reported that PI3K controls contractility of airways through regulation of Ca^{2+} oscillations in ASM cells (Jiang et al., 2010), which could be important for development of AHR in asthma. Because IL-13 may cause AHR through a direct stimulatory effect on ASM cell contraction, independent of airway inflammation, we also investigated whether targeting PI3K in ASM cells could attenuate IL-13-induced AHR in both control and IL-13-treated ASM cells. These studies are currently in progress.
PI3K in ASM cells can ameliorate AHR in an IL-13-challenged murine model of asthma. IL-13 is a one mediator of asthma, and studies aimed at blocking IL-13 in human asthma have recently shown some promise (Corren et al., 2011; Gauvreau et al., 2011); however, there are no data on effects of anti-IL-13 strategies on either the baseline or stimulated contractility underlying AHR. Because previous studies have shown that increased IL-13 is critical for the development of AHR in acute but not chronic ovalbumin challenge of mice (Taube et al., 2002; Leigh et al., 2004), it will be of interest to investigate effects of the PI3K inhibitor on AHR in acute versus chronic ovalbumin-challenge models of asthma. Such studies could further define the PI3K signaling pathway as a potential new pharmacologic target for the treatment of the AHR in multiple models of asthma.

Acknowledgments

We thank Dr. Dennis W. Wolff for analysis of Ca²⁺ signaling in ASM cells.

Authorship Contributions

Participated in research design: Jiang, Xie, Abel, Toews, Townley, Casale, and Tu.

Conducted experiments: Jiang, Xie, and Tu.

Contributed new reagents or analytic tools: Abel and Townley.

Performed data analysis: Jiang, Xie, and Abel.

Wrote or contributed to the writing of the manuscript: Jiang, Xie, Abel, Toews, Casale, and Tu.

References


Moulder JS, and Fryer AD (2003) Inositol triphosphate receptors; from folklore to finding drugs that actually work in asthma and COPD. Br J Pharmacol 139:5–52.


Address correspondence to: Yaping Tu, Department of Pharmacology, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178. E-mail: yapingTu@creighton.edu